N. David Eansor's most recent trade in Marker Therapeutics Inc was a trade of 30,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Marker Therapeutics Inc | N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Marker Therapeutics Inc | N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 12 Nov 2021 | 27,159 | 28,477 (0%) | 0% | 125.1 | 3,396,233 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2021 | 27,159 | 799 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 503.61 per share. | 12 Nov 2021 | 9,043 | 13,243 (0%) | 0% | 503.6 | 4,554,137 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.39 per share. | 12 Nov 2021 | 8,989 | 4,254 (0%) | 0% | 504.4 | 4,533,985 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 502.77 per share. | 12 Nov 2021 | 4,054 | 22,286 (0%) | 0% | 502.8 | 2,038,221 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 505.49 per share. | 12 Nov 2021 | 2,535 | 1,719 (0%) | 0% | 505.5 | 1,281,407 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2021 | 799 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 12 Nov 2021 | 799 | 2,117 (0%) | 0% | 125.1 | 99,915 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.09 per share. | 12 Nov 2021 | 700 | 27,777 (0%) | 0% | 504.1 | 352,860 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.14 per share. | 12 Nov 2021 | 537 | 26,740 (0%) | 0% | 504.1 | 270,725 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 506.24 per share. | 12 Nov 2021 | 401 | 1,318 (0%) | 0% | 506.2 | 203,002 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 505.00 per share. | 12 Nov 2021 | 400 | 26,340 (0%) | 0% | 505.0 | 202,002 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 502.99 per share. | 12 Nov 2021 | 300 | 27,277 (0%) | 0% | 503.0 | 150,897 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.78 per share. | 12 Nov 2021 | 200 | 27,577 (0%) | 0% | 504.8 | 100,956 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 503.07 per share. | 31 Aug 2021 | 1,538 | 1,318 (0%) | 0% | 503.1 | 773,728 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 8,107 | 8,107 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 6,080 | 6,080 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 2,537 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 2,537 | 3,855 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,556 | 1,556 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 999 | 2,856 (0%) | 0% | 481.8 | 481,338 | Common Stock |
| Marker Therapeutics Inc | N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 12,658 | 36,940 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | N. David Eansor | Director | Purchase of securities on an exchange or from another person at price $ 17.50 per share. | 16 Mar 2021 | 14,285 | 16,713 (0%) | 0% | 17.5 | 249,988 | Common Stock |
| Marker Therapeutics Inc | N. David Eansor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 14,285 | 2,428 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Marker Therapeutics Inc | N. David Eansor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 7,142 | 7,142 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | N. David Eansor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 7,142 | 7,142 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 05 Feb 2021 | 18,819 | 34,251 (0%) | 0% | 106.6 | 2,005,917 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 18,819 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 14,114 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 05 Feb 2021 | 14,114 | 15,432 (0%) | 0% | 106.6 | 1,504,411 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 380.50 per share. | 05 Feb 2021 | 12,833 | 10,918 (0%) | 0% | 380.5 | 4,882,918 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 378.29 per share. | 05 Feb 2021 | 6,000 | 28,251 (0%) | 0% | 378.3 | 2,269,723 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 379.62 per share. | 05 Feb 2021 | 4,500 | 23,751 (0%) | 0% | 379.6 | 1,708,312 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 382.60 per share. | 05 Feb 2021 | 3,700 | 4,318 (0%) | 0% | 382.6 | 1,415,636 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 381.52 per share. | 05 Feb 2021 | 2,900 | 8,018 (0%) | 0% | 381.5 | 1,106,395 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 384.15 per share. | 05 Feb 2021 | 1,900 | 2,418 (0%) | 0% | 384.2 | 729,888 | Common Stock |
| Bio-Techne Corp | N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 385.59 per share. | 05 Feb 2021 | 1,100 | 1,318 (0%) | 0% | 385.6 | 424,151 | Common Stock |